FDA accepts Indivior schizophrenia treatment for review

Indivior, the London-listed pharmaceuticals company, revealed its schizophrenia treatment had been accepted for review by the US Food and Drug Administration (FDA).

The FDA could decide on whether to approve Indivior´s RBP-7000 drug by July 2018.

Recent Phase III clinical trials of RBP-7000 indicated significant improvement for those suffering from acute schizophrenia.

“FDA acceptance of our RBP-7000 NDA is a significant milestone for Indivior as we expand our treatment portfolio to offer a meaningful therapeutic option to help address non-compliance with medication administration in the treatment of schizophrenia," said Christian Heidbreder, chief scientific officer of Indivior.

Indivior shares have gained 29% over the past year.

Rate this article